标题
mTORC1 and mTORC2 in cancer and the tumor microenvironment
作者
关键词
-
出版物
ONCOGENE
Volume 36, Issue 16, Pages 2191-2201
出版商
Springer Nature
发表日期
2016-10-17
DOI
10.1038/onc.2016.363
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma
- (2016) Emmanuel Seront et al. BJU INTERNATIONAL
- A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies
- (2016) Joaquin Mateo et al. BRITISH JOURNAL OF CANCER
- mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells
- (2016) Raju V. Pusapati et al. CANCER CELL
- Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers
- (2016) M. Morrison Joly et al. CANCER RESEARCH
- Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2016) S. O. Dolly et al. CLINICAL CANCER RESEARCH
- A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer
- (2016) Josep María del Campo et al. GYNECOLOGIC ONCOLOGY
- Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2016) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt
- (2016) Jinfang Zhang et al. MOLECULAR CELL
- The ever-expanding role of HIF in tumour and stromal biology
- (2016) Edward L. LaGory et al. NATURE CELL BIOLOGY
- mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle
- (2016) I. Ben-Sahra et al. SCIENCE
- Mammalian Target of Rapamycin Complex 2 Controls CD8 T Cell Memory Differentiation in a Foxo1-Dependent Manner
- (2016) Lianjun Zhang et al. Cell Reports
- A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma
- (2015) Johanna C. Bendell et al. CANCER
- Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling
- (2015) Shaogang Sun et al. CANCER CELL
- Plasticity beyond Cancer Cells and the “Immunosuppressive Switch”
- (2015) Zvi Granot et al. CANCER RESEARCH
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1
- (2015) Wilhelm Palm et al. CELL
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- Multiple amino acid sensing inputs to mTORC1
- (2015) Mitsugu Shimobayashi et al. CELL RESEARCH
- First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
- (2015) B. Basu et al. CLINICAL CANCER RESEARCH
- First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies
- (2015) P. Munster et al. CLINICAL CANCER RESEARCH
- First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
- (2015) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
- (2015) Johanna C. Bendell et al. INVESTIGATIONAL NEW DRUGS
- mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation
- (2015) Kristen N. Pollizzi et al. JOURNAL OF CLINICAL INVESTIGATION
- The role for autophagy in cancer
- (2015) Eileen White JOURNAL OF CLINICAL INVESTIGATION
- mTOR: a pharmacologic target for autophagy regulation
- (2015) Young Chul Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- Regulation of Endothelial Cell Proliferation and Vascular Assembly through Distinct mTORC2 Signaling Pathways
- (2015) Shan Wang et al. MOLECULAR AND CELLULAR BIOLOGY
- Molecular Basis of the Rapamycin Insensitivity of Target Of Rapamycin Complex 2
- (2015) Christl Gaubitz et al. MOLECULAR CELL
- Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
- (2015) Patrick Y. Wen et al. NEURO-ONCOLOGY
- CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks
- (2015) F Guo et al. ONCOGENE
- Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP
- (2015) S J H Ricoult et al. ONCOGENE
- Architecture of human mTOR complex 1
- (2015) C. H. S. Aylett et al. SCIENCE
- Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1
- (2015) S. Wang et al. SCIENCE
- Sestrin2 is a leucine sensor for the mTORC1 pathway
- (2015) R. L. Wolfson et al. SCIENCE
- Differential regulation of mTORC1 by leucine and glutamine
- (2015) J. L. Jewell et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors
- (2015) H. Cheng et al. Cancer Discovery
- PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex
- (2015) P. Liu et al. Cancer Discovery
- A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation
- (2015) Guang Yang et al. Cell Reports
- mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis
- (2015) Meghan M. Morrison et al. PLoS Genetics
- Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis
- (2015) Maikel A. Farhan et al. PLoS One
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
- (2014) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
- (2014) Carolyn D. Britten et al. INVESTIGATIONAL NEW DRUGS
- Nitrogen Source Activates TOR (Target of Rapamycin) Complex 1 via Glutamine and Independently of Gtr/Rag Proteins
- (2014) Daniele Stracka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors
- (2014) Pasi A. Jänne et al. Journal of Thoracic Oncology
- Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma
- (2014) Kyriakos P. Papadopoulos et al. LEUKEMIA & LYMPHOMA
- SGK3 Mediates INPP4B-Dependent PI3K Signaling in Breast Cancer
- (2014) Jessica A. Gasser et al. MOLECULAR CELL
- The AGC kinase SGK1 regulates TH1 and TH2 differentiation downstream of the mTORC2 complex
- (2014) Emily B Heikamp et al. NATURE IMMUNOLOGY
- Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors
- (2013) Eeva M. Sommer et al. BIOCHEMICAL JOURNAL
- Requirement for Rictor in homeostasis and function of mature B lymphoid cells
- (2013) K. Lee et al. BLOOD
- mTOR Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis
- (2013) D. Roy et al. CANCER RESEARCH
- mTOR Complex 2 Controls Glycolytic Metabolism in Glioblastoma through FoxO Acetylation and Upregulation of c-Myc
- (2013) Kenta Masui et al. Cell Metabolism
- Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2
- (2013) Sean J. Humphrey et al. Cell Metabolism
- Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer
- (2013) Sampurna Chatterjee et al. JOURNAL OF CLINICAL INVESTIGATION
- mTOR kinase structure, mechanism and regulation
- (2013) Haijuan Yang et al. NATURE
- Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis
- (2013) Pengda Liu et al. NATURE CELL BIOLOGY
- mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy
- (2013) M. Weiler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1
- (2013) I. Ben-Sahra et al. SCIENCE
- Quantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis
- (2013) A. M. Robitaille et al. SCIENCE
- Resolving Molecular Events in the Regulation of Meiosis in Male and Female Germ Cells
- (2013) S. Kumar et al. Science Signaling
- The TSC-mTOR pathway regulates macrophage polarization
- (2013) Vanessa Byles et al. Nature Communications
- Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
- (2013) J. M. Balko et al. Cancer Discovery
- Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
- (2012) B. Markman et al. ANNALS OF ONCOLOGY
- Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
- (2012) A Naing et al. BRITISH JOURNAL OF CANCER
- A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors
- (2012) Luis E. Raez et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Leucyl-tRNA Synthetase Is an Intracellular Leucine Sensor for the mTORC1-Signaling Pathway
- (2012) Jung Min Han et al. CELL
- Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
- (2012) D. Mahadevan et al. EUROPEAN JOURNAL OF CANCER
- Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia
- (2012) Keunwook Lee et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Leucyl-tRNA Synthetase Controls TORC1 via the EGO Complex
- (2012) Grégory Bonfils et al. MOLECULAR CELL
- The translational landscape of mTOR signalling steers cancer initiation and metastasis
- (2012) Andrew C. Hsieh et al. NATURE
- Dual Inhibition of the PI3K/mTOR Pathway Increases Tumor Radiosensitivity by Normalizing Tumor Vasculature
- (2011) E. Fokas et al. CANCER RESEARCH
- Activation of mTORC2 by Association with the Ribosome
- (2011) Vittoria Zinzalla et al. CELL
- mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway
- (2011) Timothy R. Peterson et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
- (2011) Y. Yu et al. SCIENCE
- The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
- (2011) P. P. Hsu et al. SCIENCE
- Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance
- (2011) K. Tanaka et al. Cancer Discovery
- Mammalian Target of Rapamycin Protein Complex 2 Regulates Differentiation of Th1 and Th2 Cell Subsets via Distinct Signaling Pathways
- (2010) Keunwook Lee et al. IMMUNITY
- Requirement of the mTOR Kinase for the Regulation of Maf1 Phosphorylation and Control of RNA Polymerase III-dependent Transcription in Cancer Cells
- (2010) Boris Shor et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1
- (2010) Katrin Düvel et al. MOLECULAR CELL
- mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1
- (2010) T. Kantidakis et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
- (2010) R. J. O. Dowling et al. SCIENCE
- mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
- (2009) David A. Guertin et al. CANCER CELL
- Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
- (2009) K. Yu et al. CANCER RESEARCH
- mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
- (2009) H. A. Lane et al. CLINICAL CANCER RESEARCH
- The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment
- (2009) Greg M. Delgoffe et al. IMMUNITY
- mTOR regulates memory CD8 T-cell differentiation
- (2009) Koichi Araki et al. NATURE
- Molecular mechanisms of mTOR-mediated translational control
- (2009) Xiaoju Max Ma et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth
- (2008) Thomas Porstmann et al. Cell Metabolism
- Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation
- (2008) Audrey Carrière et al. CURRENT BIOLOGY
- The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
- (2008) Y. Sancak et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started